{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=22",
    "query": {
      "intervention": "Active Comparator (Product-B)",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 618,
    "total_pages": 62,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+%28Product-B%29&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:59:45.769Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06733675",
      "title": "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Pharmacokinetics",
        "Safety",
        "Drug-Drug Interaction (DDI)",
        "FDC"
      ],
      "interventions": [
        {
          "name": "Ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten-ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "amoxicillin-clavulanate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-01-07",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733675"
    },
    {
      "nct_id": "NCT05651828",
      "title": "Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Advanced Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Vismodegib 150 MG Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2023-03-23",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05651828"
    },
    {
      "nct_id": "NCT03980314",
      "title": "A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 261,
      "start_date": "2019-06-24",
      "completion_date": "2023-11-06",
      "has_results": false,
      "last_update_posted_date": "2023-12-15",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 4,
      "location_summary": "Hartford, Connecticut • Minneapolis, Minnesota • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03980314"
    },
    {
      "nct_id": "NCT00590122",
      "title": "Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Parcopa",
          "type": "DRUG"
        },
        {
          "name": "carbidopa-levodopa (Sinemet)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "31 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "31 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00590122"
    },
    {
      "nct_id": "NCT04071223",
      "title": "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Kidney Medullary Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Papillary Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unclassified Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radium Ra 223 Dichloride",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2020-07-29",
      "completion_date": "2027-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071223"
    },
    {
      "nct_id": "NCT00853892",
      "title": "Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Controlled-Release Oxycodone Hydrochloride 40 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "OxyContin® 40 mg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2005-04",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853892"
    },
    {
      "nct_id": "NCT06067828",
      "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Budesonide and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment C : Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 171,
      "start_date": "2023-10-24",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067828"
    },
    {
      "nct_id": "NCT04643067",
      "title": "Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SLE; Drug"
      ],
      "interventions": [
        {
          "name": "KPG-818 low dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 mid dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 high dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 ultra-high dose in phase 1b",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 low dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 mid dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 high dose in phase 2a",
          "type": "DRUG"
        },
        {
          "name": "KPG-818 Placebo in phase 2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-06-03",
      "completion_date": "2023-06-29",
      "has_results": true,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 18,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Clearwater, Florida + 12 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Cutler Bay",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04643067"
    },
    {
      "nct_id": "NCT07177079",
      "title": "High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "High-dose ascorbate",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kittika Poonsombudlert",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-03-18",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07177079"
    },
    {
      "nct_id": "NCT02641561",
      "title": "Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post-ERCP Acute Pancreatitis"
      ],
      "interventions": [
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Lactated Ringer's Solution",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cooper Norcross Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2014-10",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-11-19T09:59:45.769Z",
      "location_count": 1,
      "location_summary": "Camden, New Jersey",
      "locations": [
        {
          "city": "Camden",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641561"
    }
  ]
}